Arrowhead Pharmaceuticals... (ARWR)
NASDAQ: ARWR
· Real-Time Price · USD
28.63
-0.04 (-0.14%)
At close: Sep 16, 2025, 10:43 AM
-0.14% (1D)
| Bid | 28.62 |
| Market Cap | 3.96B |
| Revenue (ttm) | 596.57M |
| Net Income (ttm) | -148.42M |
| EPS (ttm) | -1.2 |
| PE Ratio (ttm) | -23.86 |
| Forward PE | -9.59 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 28.74 |
| Volume | 268,863 |
| Avg. Volume (20D) | 2,332,738 |
| Open | 28.75 |
| Previous Close | 28.67 |
| Day's Range | 28.53 - 29.18 |
| 52-Week Range | 9.57 - 31.13 |
| Beta | 1.01 |
| Ex-Dividend Date | n/a |
About ARWR
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ARWR
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ARWR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsArrowhead Pharmaceuticals Inc. is scheduled to release its earnings on
Nov 25, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
+16.57%
Arrowhead Pharmaceuticals shares are trading highe...
Unlock content with
Pro Subscription
1 month ago
-1.53%
Arrowhead Pharmaceuticals shares are trading lower after the company reported a Q3 EPS miss.
1 month ago · seekingalpha.com
Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2025 Earnings Call TranscriptArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Q3 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Andy Davis - SVP of Cardiovascular & Head of Metabolic Franchise Bruce D....